On the 7th of January, Orbimed Advisors sold 2 million CTI BioPharma Corp. (NASDAQ:) shares for $7 million at an average price of $3.50 per share.
Shares of CTI BioPharma Corp. are down -2.27% since the transaction.
Orbimed Advisors’s holding in CTI BioPharma Corp. decreased to about 7.5 million shares with the transaction.
Orbimed Advisors first bought CTI BioPharma Corp. stock in the second quarter of 2017.
Orbimed Advisors also owns Bristol-Myers Squibb Co (NYSE:), Merck (MRK), Larimar Therapeutics, Inc. (LRMR) and Mirati Therapeutics Inc (NASDAQ:).
CTI BioPharma Corp. is its number thirty six position by number of shares and market value among biotechnology & life sciences stocks.
Other investors who also reduced their CTI BioPharma Corp. shares include Victory Capital Management.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.